The association of EGFR with the concerning phenotype of CPI-induced hyper-progression characterised by accelerated tumour growth and clinical deterioration [21, 44] indicates further caution for the use of CPIs in EGFR-driven tumours, including ESCCs [19, 20]. Here, EGFR is linked to neoplasm.